Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2022;33(1):14-34
Article Links
Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study
Prodromos Sidiropoulos1, Andreas Bounas2, Nikolaos Galanopoulos3, Georgios Vosvotekas4, Eftichia Maria Koukli5, Panagiotis Georgiou6, Nikolaos Marketos7, Tina Antachopoulou8, Antonios Kyriakakis8, Maria Koronaiou8
Authors Information

1. Rheumatology, Clinical Immunology and Allergy, Medical School, University of Crete, Heraklion, Greece
2. OLYMPION Hospital-General Clinic of Patras, Patras, Greece
3. Outpatient Department of Rheumatology, University General Hospital of Alexandroupolis, Thrace, Greece
4. EUROMEDICA General Clinic of Thessaloniki, Thessaloniki, Greece
5. IASIO Hospital-General Clinic of Kallithea, Athens, Greece
6. Department of Rheumatology, General Hospital of Patras “Agios Andreas”, Patras, Greece
7. Private Clinic Henry Dunant Hospital Centre, Athens, Greece;
8. Medical Department, AbbVie Pharmaceuticals S.A., Neo Iraklio, Athens, Greece

P Sidiropoulos, A Bounas, N Galanopoulos, G Vosvotekas, EM Koukli, P Georgiou, N Marketos, T Antachopoulou, A Kyriakakis, M Koronaiou

Keywords: rheumatoid arthritis, DMARDs, adherence, satisfaction, patient-reported outcomes, patient perspectives
References
  1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010; 376:1094-1108.
  2. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020 Jun;79(6):685-99.
  3. Genitsaridi I FI, Repa A, Avgoustidis N, Kougkas N, Papalopoulos I, Polia S, et al. In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome [abstract]. Arthritis Rheumatol 2018;70 (suppl 10).
  4. Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69(3):536-41.
  5. Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, et al.  Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status. Clin Exp Rheumatol 2016;34(6):999-1005.
  6. Flouri I, Drosos A, Boki K, Skopouli F, Karras D, Papadopoulos I, et al.  Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults. Clin Exp Rheumatol 2009;27(5):705-6.
  7. Flouri I, Markatseli T, Voulgari P, Boki K, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014;43(4):447-57.
  8. Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, et al.  Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterr J Rheumatol 2018;29(1):27-37.
  9. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, et al. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017;35(4):579-85.
  10. Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daurès JP, et al.  Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort. Ann Rheum Dis 2015;74(4):724-9.
  11. Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh DA, et al.  Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis 2016;75(12):2080-6.
  12. Michetti P, Wadstrm T, Kraehenbuhl JP, Lee A, Kreiss C, Blum AL. Frontiers in Helicobacter pylori research: pathogenesis, host response, vaccine development and new therapeutic approaches. Eur J Gastroenterol Hepatol 1996;8(7):717-22.
  13. Durand C, Eldoma M, Marshall DA, Bansback N, Hazlewood GS. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. J Rheumatol 2020;47(2):176-87.
  14. Bywall KS, Kihlbom U, Hansson M, Falahee M, Raza K, Baecklund E, et al.  Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients. Arthritis Res Ther 2020;22(1):288.
  15. Taylor PC, Ancuta C, Nagy O, De la Vega MC, Gordeev A, Janková R, et al.  Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Patient Preference Adherence 2021;15:359-73.
  16. Barton JL, Markwardt S, Niederhausen M, Schue A, Dougherty J, Katz P, et al. Are We on the Same Page?: A Cross-Sectional Study of Patient-Clinician Goal Concordance in Rheumatoid Arthritis. Arthritis Care Res 2021. https://doi.org/10.1002/acr.24794
  17. Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, et al.  Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. RMD Open 2020;6:e001290.
  18. Jackson JL, Chamberlin J, Kroenke K. Predictors of patient satisfaction. Soc Sci Med 2001;52(4):609-20.
  19. Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, et al.  Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm 2019;25(7):770-9.
  20. Van den Bosch F, Ostor AJK, Wassenberg S, Chen N, Wang C, Garg V, et al.  Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study. Rheumatol Ther 2017;4(1):85-96.
  21. Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.  Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm 2017;23(8):859-67.
  22. Marengo MF and Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol 2015;10(5):345-56.
  23. Kvien TK, Balsa A, Betteridge N, Buch MH, Durez P, Favalli EG, et al.  Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. RMD Open 2020;6(2).
  24. Norman CD, Skinner HA. eHealth Literacy: Essential Skills for Consumer Health in a Networked World. J Med Internet Res 2006;8(2):e9.
  25. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al.  Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007;66(1):28-33.
  26. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 2008;10(3):207.
  27. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J. Rheumatol 2006; 33(12):2440-6.
  28. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al.  Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009;29(10):1702-8.
  29. Stamatelopoulos KS, Kitas GD, Papamichael CM, Kyrkou K, Zampeli E, Fragiadaki K, et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis 2010;212(1):305-9.
  30. Thomas K, Kaltsonoudis E, Drosos A, Papalopoulos I, Sidiropoulos P, Katsimbri P, et al.  SAT0176 Patterns of biologic DMARD monotherapy in a large nationwide rheumatoid arthritis cohort: data from 1036 patients. Ann Rheum Dis 2017;76(Suppl 2):836-7.
  31. Thomas K, Lazarini A, Kaltsonoudis E, Drosos A, Tsatsani P, Gazi S, et al.  THU0102 High rates of residual disease activity despite current therapies in a real life rheumatoid arthritis cohort: data from 1096 patients [abstract]. Ann Rheum Dis 2018;77(Suppl 2):272-3.
  32. Toutouzas K, Sfikakis PP, Karanasos A, Aggeli C, Felekos I, Kitas G, et al.  Myocardial ischaemia without obstructive coronary artery disease in rheumatoid arthritis: hypothesis-generating insights from a cross-sectional study. Rheumatology (Oxford) 2013;52(1):76-80.
  33. Zampeli E, Protogerou A, Stamatelopoulos K, Fragiadaki K, Katsiari C, Kyrkou K, et al.  Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 2012;14(2):R44.
  34. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al.  Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12.
  35. Radawski C, Genovese MC, Hauber B, Nowell WB, Hollis K, Gaich CL, et al.  Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. Rheumatol Ther 2019;6(3):461-471.
  36. Fries JF, Spitz P, Kraines RG, Holman HR.  Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23(2):137-45.
  37. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13(2):63-74.
  38. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4(5):353-65.
  39. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473-83.
  40. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC.  Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25(9):2303-10.
  41. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 2016;35(5):1335-9.
  42. Mahlich J, Schaede U, Sruamsiri R. Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment. Rheumatol Ther 2019;6(2):269-83.
  43. Richtering SS, Hyun K, Neubeck L, Coorey G, Chalmers J, Usherwood T, et al. eHealth Literacy: Predictors in a Population With Moderate-to-High Cardiovascular Risk. JMIR Hum Factors 2017;4(1):e4.
  44. Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE. An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. Rheumatol Int 2012;32(9):2725-9.
  45. Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 2012;64(9):2814-23.
  46. Taylor PC, Ancuta C, Nagy O, Delavega M, Gordeev A, Janková R, et al. SAT0123 Treatment Satisfaction, Expectations, Patient Preferences and characteristics, including Digital Health Literacy (DHL), and the impact of suboptimal disease control in a large international cohort of patients with Rheumatoid Arthritis (RA): The SENSE Study [abstract]. Ann Rheum Dis 2020;79(Suppl 1):996.
  47. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007;56(7):2135-42.
  48. Takahashi N, Sasaki K, Nishiyama T, Naniwa T. Satisfaction and attitudes toward therapy in patients with rheumatoid arthritis. Mod Rheumatol 2012;22(3):376-381.
  49. Hendrikx J, Kievit W, Fransen J, van Riel P. The influence of patient perceptions of disease on medication intensification in daily practice. Rheumatology (Oxford) 2016;55(11):1938-45.
  50. Fanouriakis A, Papalopoulos I, Gergianaki I, Spyrou G, Erden A, Rapsomaniki P, et al. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. Clin Exp Rheumatol 2018;36(5):806-13.
  51. Ramiro S, Landewé RB, van der Heijde D, Sepriano A, FitzGerald O, Ostergaard M, et al. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Ann Rheum Dis 2020;79(4):453-9.
  52. Khunti K, Gomes M.B, Pocock S, Shestakova M.V, Pintat S, Fenici P, et al.  Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab 2018;20:427-37.
  53. Gavigan K, Nowell WB, Serna MS, Stark JL, Yassine M, Curtis JR. Barriers to treatment optimization and achievement of patients’ goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry. Arthritis Res Ther 2020;22(1):4.
  54. van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, et al. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open 2016;2(2):e000302.
  55. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. Aids 2002;16(2):269-77.
  56. Thomas K, Lazarini A, Kaltsonoudis E, Drosos A, Papalopoulos I, Sidiropoulos P, et al. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Ther Adv Musculoskel Dis 2020;12:1-12.